RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Immunogenicity of Trivalent Influenza Vaccine in Extremely Low-birth-weight, Premature versus Term Infants. ... (HA) units in 0.025 mL of the virus suspension. H1, H3, B/Victoria, ...

Spanning nine influenza seasons, these studies enrolled 1862 patients, of whom 954 received the high-dose vaccine and 908 the standard-dose vaccine. Primary outcomes were immunogenicity (measured ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines ...

"An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic ... pivotal efficacy, immunogenicity and ...

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines ...

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines ...

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines ...